



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 17740

Title: Severe immune thrombocytopenia after Peg-Interferon-alpha2a, Ribavirin and Telaprevir treatment completion: a case report and systematic review of literature.

Reviewer's code: 00542396

Reviewer's country: Spain

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-22 10:35

Date reviewed: 2015-04-07 00:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> [Y] Grade B: Very good	<input type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> [] Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Authors report a rare case of AITP in a very particular population. Although the results might be representative of just a low portion of the general population, it still interesting to get it published. To associate a hematological disorder to a patient under a particular medication is relatively straight forward, but being able to associate these symptoms after a period of time upon medication was provided is much more difficult and for this reason I consider this manuscript should be published. It might help and warn to professionals in similar situation that are not able to localize the focus of the hematological alterations. The manuscript is well written and it is completed with an appropriate review of the literature, thus I encourage the publication of this manuscript in its present form. Minor points. -Please verify IUPAC nomenclature in order to present the abbreviation of the magnitudes, such as microL, or l instead of L, mmc instead of mm3 or cc. - Please check whether immunoglobulin IV is well written. -In "comments" section, please verify the sentence under the "Treatment" heading. -Please verify the reference section. Some references are not well written and the format should be uniform throughout the section.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 17740

Title: Severe immune thrombocytopenia after Peg-Interferon-alpha2a, Ribavirin and Telaprevir treatment completion: a case report and systematic review of literature.

Reviewer's code: 00160603

Reviewer's country: Indonesia

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-22 10:35

Date reviewed: 2015-04-09 14:03

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

There are several issues in this case report: 1. How the author confirmed that the autoimmune condition not a concomitant or might be due to HCV infection? It should be discussed more clearly. 2. Please mentioned with numeric when mention about lab result (how much was decreased of HCV RNA?) 3. Beside awareness there is no other new issue about this report.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 17740

Title: Severe immune thrombocytopenia after Peg-Interferon-alpha2a, Ribavirin and Telaprevir treatment completion: a case report and systematic review of literature.

Reviewer's code: 00069297

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-22 10:35

Date reviewed: 2015-03-25 10:43

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The Title describes the contents of the paper. The Abstract is informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The purpose or purported significance of the article is explicitly stated. The research study methods are complete enough to allow experiments to be reproduced. All Figure and table are necessary and appropriate. The Results are presented with clarity and precision. The Discussion interprets the findings in view of the results obtained in this and in past studies on this topic.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 17740

Title: Severe immune thrombocytopenia after Peg-Interferon-alpha2a, Ribavirin and Telaprevir treatment completion: a case report and systematic review of literature.

Reviewer’s code: 01553776

Reviewer’s country: Japan

Science editor: Xue-Mei Gong

Date sent for review: 2015-03-22 10:35

Date reviewed: 2015-03-29 15:37

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Major points: This is a case report of AITP following peg-IFN treatment withdrawal. The authors comment that AITP occurs during peg-IFN treatment and rarely even after completion of peg-IFN treatment. Most debatable issue in this manuscript is if mechanisms of AITP occurring after completion of treatment differs from AITP occurring during treatment. If not, the basis for reporting this case as a special does not make sense. The authors claim that peg-IFN-induced autoimmune diseases may appear even after treatment withdrawal, because of long-half-life of peg-IFN. However, AITP occurred at 24 weeks after withdrawal in another case in the Table, in which this long withdrawal duration does not fit their hypothesis. Based on the data in Table 1, AITP occurs at 1 week to 144 weeks of treatment, widely distributed. It is desirable if the authors cite and discuss the mechanisms in other drug-autoimmune phenomenon occurring after completion of treatment, not in the HCV-IFN situation. Minor points: (1) Abstract new DDAs? (2) Introduction, what’s DDAs? (3) In Discussion, drug-induced AIT (why here AIT, not AITP)?